Outcome based on day-22 bone marrow and day-8 blood MRD results and the reatment arm
| MRD . | HD-ADE . | Clo/AraC . | ||||
|---|---|---|---|---|---|---|
| N . | 3-year EFS . | 3-year OS . | N . | 3-year EFS . | 3-year OS . | |
| BM-positive | ||||||
| Blood-positive | 28 | 10.7% ± 6% | 26.8% ± 9% | 35 | 49.8% ± 9% | 64.0% ± 8% |
| Blood-negative | 10 | 80.0% ± 3% | 90.0% ± 10% | 14 | 53.3% ± 13% | 72.2% ± 12% |
| BM-negative | ||||||
| Blood-positive | 18 | 71.8% ± 11% | 83.0% ± 9% | 9 | 55.6% ± 17% | 77.8% ± 14% |
| Blood-negative | 52 | 62.1% ± 7% | 76.1% ± 6% | 44 | 71.2% ± 7% | 88.1% ± 5% |
| MRD . | HD-ADE . | Clo/AraC . | ||||
|---|---|---|---|---|---|---|
| N . | 3-year EFS . | 3-year OS . | N . | 3-year EFS . | 3-year OS . | |
| BM-positive | ||||||
| Blood-positive | 28 | 10.7% ± 6% | 26.8% ± 9% | 35 | 49.8% ± 9% | 64.0% ± 8% |
| Blood-negative | 10 | 80.0% ± 3% | 90.0% ± 10% | 14 | 53.3% ± 13% | 72.2% ± 12% |
| BM-negative | ||||||
| Blood-positive | 18 | 71.8% ± 11% | 83.0% ± 9% | 9 | 55.6% ± 17% | 77.8% ± 14% |
| Blood-negative | 52 | 62.1% ± 7% | 76.1% ± 6% | 44 | 71.2% ± 7% | 88.1% ± 5% |
BM, bone marrow; EFS, event-free survival; OS, overall survival.